Cinryze® (C1 esterase inhibitor [human])

Cinryze is covered for prophylaxis of hereditary angioedema (HAE) and for treatment of acute HAE attacks (compendial use) in patients with HAE type I or II who have baseline lab confirmation of low functional C1‑INH (<50% of normal) and low serum C4, and when prescribed by or in consultation with an allergist/immunologist or HAE specialist. Initial and reauthorizations are for 12 months (reauthorization requires documented clinical benefit — reduced attack frequency, severity, or duration), and dosing must follow age‑specific limits (≥12 yrs: 1,000 IU IV q3–4 days, up to 2,000 IU/not >80 IU/kg; 6–11 yrs: 500 IU IV q3–4 days, up to 1,000 IU).

"Prophylaxis against Hereditary Angioedema (HAE) attacks (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.